Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Captures Overall Composite Edge (28.0 SELL vs 48.9 HOLD), While AYTU Leads 4–2 on Growth & Valuation Pillars

CAPR Overall Winner 6-Pillar Tally: CAPR 2 – 4 AYTU Matrix Metrics: CAPR 4 – 6 AYTU

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. CAPR trades at $8.47 (78.7x Forward P/E, 0.0% operating margin) versus AYTU at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY).
  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs AYTU
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (CAPR 2 – 4 AYTU)

Columns: Metric · CAPR · AYTU
1. Valuation Multiples AYTU
Forward P/E 78.7x 9.2x
Trailing P/E 78.7x 9.2x
PEG Ratio 0.38x N/M
EV / Revenue 57.8x 0.3x
2. Growth & Scale AYTU
Revenue Growth (YoY) -7.9% +6.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $58M
Market Cap $595.4M $19.6M
3. Profitability & Quality CAPR
Gross Margin N/A 64.0%
Operating Margin 0.0% -14.4%
Net Profit Margin 0.0% -24.8%
Return on Equity (ROE) -100.5% -52.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$146M -$1.4M
Cash Flow Margin N/A -2.4%
Net Cash / Leverage $48M Net Debt (0.44x D/E) $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 637.1% (89th %ile) N/A (N/A)
Put/Call OI Skew 1.57x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity N/A 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (4) vs AYTU (6)
Institutional Metric CAPR AYTU Criterion Row Edge
Market Capitalization
Scale
$595.4M $19.6M Larger Scale CAPR
Trailing P/E Ratio
Valuation
78.7x 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
78.7x 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
-7.9% +6.4% Higher Growth AYTU
Operating Margin (TTM)
Profitability
0.0% -14.4% Higher Margin CAPR
Net Profit Margin
Profitability
0.0% -24.8% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-100.5% -52.5% Higher ROE AYTU
52-Week Range Position
Momentum
15% ($3–$40) 5% ($2–$3) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$11M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +37.5 pp
CAPR: +26.23% · AYTU: -11.27%
3M Horizon CAPR +42.94 pp
CAPR: +19.63% · AYTU: -23.31%
6M Horizon AYTU +53.23 pp
CAPR: -70.58% · AYTU: -17.35%
1Y Horizon CAPR +58.93 pp
CAPR: +46.79% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAPR Revenue AYTU Revenue CAPR Op. Margin AYTU Op. Margin Margin Leader
FY2019 $0M $10M -769.5% -230.1% AYTU
FY2020 $0M $30M -4412.6% -76.5% AYTU
FY2021 $0M $70M -8549.9% -89.7% AYTU
FY2022 $0M $100M -1163.9% -113.7% AYTU
FY2023 $30M $110M -95.6% -15.9% AYTU
FY2024 $20M $70M -191.1% -2.4% AYTU
FY2025 N/A $70M N/A -11.8% AYTU
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. CAPR trades at $8.47 (78.7x Forward P/E, 0.0% operating margin) versus AYTU at $1.81 (9.2x Forward P/E, -14.4% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CAPR cumulative revenue shifted -33.3% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.